ArticleCell cycle (Georgetown, Tex.)2014
miR-34a is essential for p19(Arf)-driven cell cycle arrest.
Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- The comprehensive landscape of miR-34a in cancer research.Cancer metastasis reviews · 2021Review
- Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis.Biomolecules · 2021Review
- Dual Role of the Alternative Reading Frame ARF Protein in Cancer.Biomolecules · 2019Review
- Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro.Scientific reports · 2018Article
- Article
- Alternative mechanisms of miR-34a regulation in cancer.Cell death & disease · 2017Review
- Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.Oncotarget · 2016Article
- Loss-of-function screening to identify miRNAs involved in senescence: tumor suppressor activity of miRNA-335 and its new target CARF.Scientific reports · 2016Article
- p19(Arf) limits primary vitreous cell proliferation driven by PDGF-B.Experimental eye research · 2016Article
- A feedback regulatory loop involving p53/miR-200 and growth hormone endocrine axis controls embryo size of zebrafish.Scientific reports · 2015Article
- MiR-34a regulates blood-tumor barrier function by targeting protein kinase Cε.Molecular biology of the cell · 2015Article
- Epigenetic programming of hypoxic-ischemic encephalopathy in response to fetal hypoxia.Progress in neurobiology · 2015Review
- Mir-34: a new weapon against cancer?Molecular therapy. Nucleic acids · 2014Review
- Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis.Oncotarget · 2014Article
- Isolation and characterization of mammalian cells expressing the Arf promoter during eye development.BioTechniques · 2014Article
- ARF sees Pdgfrβ through the miR.Cell cycle (Georgetown, Tex.) · 2014Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The Arf tumor suppressor gene product, p19(Arf), regulates cell proliferation in incipient cancer cells and during embryo development. Beyond its commonly accepted p53-dependent actions, p19(Arf) also acts independently of p53 in both contexts. One such p53-independent effect with in vivo relevance includes its repression of Pdgfrβ, a process that is essential for vision in the mouse. We have utilized cell culture-based and mouse models to define a new role for miR-34a in this process. Ectopic expression of Arf in cultured cells enhanced the expression of several microRNAs predicted to target Pdgfrß synthesis, including the miR-34 family. Because miR-34a has been implicated as a p53-dependent effector, we investigated whether it also contributed to p53-independent effects of p19(Arf). Indeed, in mouse embryo fibroblasts (MEFs) lacking p53, Arf-driven repression of Pdgfrβ and its blockade of Pdgf-B stimulated DNA synthesis were both completely interrupted by anti-microRNA against miR-34a. Ectopic miR-34a directly targeted Pdgfrβ and a plasmid reporter containing wild-type Pdgfrβ 3'UTR sequence, but not one in which the miR-34a target sequence was mutated. Although miR-34a expression has been linked to p53-a well-known effector of p19(Arf)-Arf expression and its knockdown correlated with miR-34a level in MEFs lacking p53. Finally, analysis of the mouse embryonic eye demonstrated that Arf controlled expression of miR-34a, and the related miR-34b and c, in vivo during normal mouse development. Our findings indicate that miR-34a provides an essential link between p19(Arf) and its p53-independent capacity to block cell proliferation driven by Pdgfrβ. This has ramifications for developmental and tumor suppressor roles of Arf.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.